GlassScriptPhysician profile
Cindy Chen
NPI 1023756053
$7,449.61
in general payments reported to CMS, 2019-2025
23 companies · $7,181 in 2025
The $7,181 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $244).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $269 · 2025: $7,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,328 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,327.97 |
| Education | $121.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,059.59 | 2025 | |
| Janssen Pharmaceuticals, INC | $920.58 | 2024-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $737.87 | 2024-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $718.12 | 2024-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $691.48 | 2024-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $659.21 | 2024-2025 | |
| Alkermes, INC. | $573.63 | 2025 | Aristada, Lybalvi, Aristada Initio |
| Vanda Pharmaceuticals INC. | $539.14 | 2024-2025 | Fanapt |
| Lundbeck LLC | $295.16 | 2025 | Rexulti |
| Noven Therapeutics, LLC | $213.05 | 2025 | Xelstrym |
| Axsome Therapeutics, INC. | $212.12 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $171.09 | 2025 | Trintellix |
| Biogen, INC. | $169.40 | 2024-2025 | Zurzuvae |
| E.R. Squibb & Sons, L.L.C. | $146.29 | 2025 | Cobenfy |
| Indivior INC. | $87.01 | 2025 | Sublocade |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $84.90 | 2025 | Brixadi |
| Idorsia Pharmaceuticals US INC | $59.52 | 2025 | Quviviq |
| Lilly USA, LLC | $27.79 | 2025 | Zepbound |
| Collegium Pharmaceutical, INC. | $22.91 | 2025 | Jornay Pm |
| Tempus Ai, INC | $18.00 | 2024 | |
| Azurity Pharmaceuticals, INC. | $17.65 | 2025 | |
| Tris Pharma INC | $14.41 | 2025 | Onyda Xr |
| Corium, LLC | $10.69 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cindy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.